EditCo Bio and Promega have announced a strategic licensing agreement that grants EditCo access to Promega’s HiBiT, HaloTag, and NanoLuc technologies. Under the terms of the arrangement, EditCo will incorporate Promega’s bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines. According to the partners, the combined solutions will allow customers to generate precise gene edits in cell lines with functional validation.
Promega’s HiBiT technology is a small bioluminescent peptide tag for quantitative analysis of protein expression and interactions in live cells. The HaloTag is a protein labeling system that relies on covalently attaching fluorescent and bioluminescent probes for use in imaging, protein interaction studies, and biochemical assays. Finally, the NanoLuc technology is a luciferase enzyme that provides a bioluminescent signal for monitoring cellular and molecular processes in real-time.
Through this agreement, EditCo will be able to facilitate precise genomic knock-ins and also offer functional validation services that ensure that engineered cells maintain proper protein expression, stability, and activity. Cell models produced from the combined capabilities could be used for mechanistic studies, drug screening, and other advanced applications that require quantitative protein analysis.
Integrating HiBiT, HaloTag, and NanoLuc into EditCo’s knock-in workflows provides researchers with “powerful tools to track protein expression, interactions, and activity with high sensitivity and accuracy,” said Travis Maures, PhD, CSO at EditCo Bio. Specifically, scientists will be able to “probe protein dynamics directly within living cells, empowering deeper insights into complex biological mechanisms,” added Tom Livelli, Promega’s vice president for life sciences.
Earlier this year, EditCo launched XDel Knockout Cells, a new CRISPR-based gene editing product that uses up to three guideRNAs to create fragment deletions in target genes.
At the time of the launch, Maures explained to GEN that the guides work cooperatively, meaning that as each individual one binds, it unwinds the DNA in a way that makes it easier for the next one to bind. The result is a “product where the knockout percent is in the high 90s,” he said. Furthermore, because it’s so efficient, “we can titrate down the dose that the cells get of guides and CRISPR complexes,” which reduces the risks of off-target effects, he added. “That’s also part of the optimization of our process.”
The product is available in a variety of customizable formats, including cell pools, cell clones, and engineered cell libraries. Researchers can select from immortalized cells or induced pluripotent stem cells, either customer-supplied or EditCo-supplied.
The post EditCo, Promega to Combine CRISPR Knock-In Capabilities with Protein-Labeling Tech appeared first on GEN - Genetic Engineering and Biotechnology News.
Promega’s HiBiT technology is a small bioluminescent peptide tag for quantitative analysis of protein expression and interactions in live cells. The HaloTag is a protein labeling system that relies on covalently attaching fluorescent and bioluminescent probes for use in imaging, protein interaction studies, and biochemical assays. Finally, the NanoLuc technology is a luciferase enzyme that provides a bioluminescent signal for monitoring cellular and molecular processes in real-time.
Through this agreement, EditCo will be able to facilitate precise genomic knock-ins and also offer functional validation services that ensure that engineered cells maintain proper protein expression, stability, and activity. Cell models produced from the combined capabilities could be used for mechanistic studies, drug screening, and other advanced applications that require quantitative protein analysis.
Integrating HiBiT, HaloTag, and NanoLuc into EditCo’s knock-in workflows provides researchers with “powerful tools to track protein expression, interactions, and activity with high sensitivity and accuracy,” said Travis Maures, PhD, CSO at EditCo Bio. Specifically, scientists will be able to “probe protein dynamics directly within living cells, empowering deeper insights into complex biological mechanisms,” added Tom Livelli, Promega’s vice president for life sciences.
Earlier this year, EditCo launched XDel Knockout Cells, a new CRISPR-based gene editing product that uses up to three guideRNAs to create fragment deletions in target genes.
At the time of the launch, Maures explained to GEN that the guides work cooperatively, meaning that as each individual one binds, it unwinds the DNA in a way that makes it easier for the next one to bind. The result is a “product where the knockout percent is in the high 90s,” he said. Furthermore, because it’s so efficient, “we can titrate down the dose that the cells get of guides and CRISPR complexes,” which reduces the risks of off-target effects, he added. “That’s also part of the optimization of our process.”
The product is available in a variety of customizable formats, including cell pools, cell clones, and engineered cell libraries. Researchers can select from immortalized cells or induced pluripotent stem cells, either customer-supplied or EditCo-supplied.
The post EditCo, Promega to Combine CRISPR Knock-In Capabilities with Protein-Labeling Tech appeared first on GEN - Genetic Engineering and Biotechnology News.